Skip to content
AdAdvertisement
Value Science Weekly — health economics and market access, in your inbox

Latest News — Page 4

Painted scene of a Portuguese town square: a woman counts coins at a market stall beside oranges and ceramic tiles

Big Data Analysis Free account

Portugal Outpatient Medicine Spend Rises 7.9%, Led by Diabetes Drugs

Portugal’s outpatient medicine bill rose 7.9% in January to August 2026. Antidiabetics drove nearly a third of the increase, and semaglutide spend rose 54.5%. #SyenzaNews #MarketAccess #HealthEconomics

Syenza TeamRead ›
Clinical experts discuss a medical device in a hospital consultation room

Europe Free account

Orphan Medical Devices Pilot Closes With 13 Positive Status Opinions

The EMA orphan medical devices pilot ran from August 2024 to March 2026. All 13 finalised procedures gave positive orphan status advice, and the service is now established. #SyenzaNews #MedTech #MarketAccess

Syenza TeamRead ›
Doctors and engineers talking together in a sunlit Mediterranean town square around a glowing medical device

Europe Free account

EMA Expert Panel Advice Pilot Ends With a Streamlined 60-Day Procedure

EMA’s expert panel advice pilot for high-risk medical devices closed in February 2026 with 27 advice procedures finalised. Average advice time fell from 112 days in phase one to 86 in phase two, and a 60-day procedure followed. #SyenzaNews #MedicalDevices #HTA #MarketAccess

Syenza TeamRead ›
individualised gene therapies for rare diseases

Diseases

Individualised gene therapies for rare diseases: FDA draft guidance

The FDA’s draft guidance lets sponsors add new patient-specific variants to one BLA without new trials, while CMS plans to broaden its gene therapy access model.

Syenza TeamRead ›
KRAS G12C inhibitor divarasib

Clinical Practice

KRAS G12C inhibitor divarasib outperforms approved drugs

The KRAS G12C inhibitor divarasib improved survival versus sotorasib or adagrasib in the phase III Krascendo 1 trial. #SyenzaNews #oncology #NSCLC

Syenza TeamRead ›
Novartis core operating income

Europe

Novartis core operating income rises, 2026 outlook raised

Novartis core operating income rose 10% at constant exchange rates in Q3 2026, and 2026 guidance for the measure was raised. #SyenzaNews #MarketAccess

Syenza TeamRead ›
izalontamab brengitecan breast cancer

Clinical Practice

Izalontamab brengitecan breast cancer: 59% lower risk of progression

Phase 3 PANKU-Breast01 data show izalontamab brengitecan cut the risk of disease progression or death by 59% versus chemotherapy in HR-positive, HER2-negative breast cancer. #SyenzaNews #breastcancer #oncology

Syenza TeamRead ›
Keytruda monotherapy endometrial cancer

Clinical Practice

Keytruda Monotherapy Endometrial Cancer: 43% Risk Reduction

Keytruda monotherapy cut the risk of progression or death by 43% against platinum chemotherapy in dMMR endometrial cancer, in the KEYNOTE-C93 Phase 3 trial. #SyenzaNews #oncology #precisionmedicine #endometrialcancer

Syenza TeamRead ›
Endometriosis and fibroid tablets in England

Europe

Endometriosis and fibroid tablets in England: prescriptions soar

NHS use of NICE-recommended endometriosis and fibroid tablets in England more than tripled in a year, from 1.2 million to 3.7 million tablets. #SyenzaNews #MarketAccess

Syenza TeamRead ›
JNJ-6143 prostate cancer

Clinical Practice

JNJ-6143 prostate cancer: 75% tumor response in Phase 1 trial

JNJ-6143, an investigational first-in-class oral molecule, produced a 75% tumor response rate among patients with measurable disease in a Phase 1 study. #SyenzaNews #prostatecancer #oncology

Syenza TeamRead ›
claudin 18.2 antibody-drug conjugate

Clinical Practice

Claudin 18.2 antibody-drug conjugate prolongs survival in gastro-oesophageal cancer

Sone-Ve doubled median overall survival versus investigator’s choice in third-line and later gastro-oesophageal cancer; second-line PFS missed significance.

Syenza TeamRead ›
obesity drug reimbursement in Portugal

Diseases

Obesity drug reimbursement in Portugal: new SNS terms

Portaria n.º 464/2026/1 limits state reimbursement for obesity medicines to SNS patients in a hospital obesity pathway. Cover is 15% for 12 months. #SyenzaNews #MarketAccess

Syenza TeamRead ›
Illustration of a stone courthouse beside a clinic in a sunlit village square

Diseases Free account

Antiretroviral Tender Awards Declared Invalid by Pretoria Court

A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla’s review succeeded on all five grounds, while Hetero’s challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV

Syenza TeamRead ›
Intismeran adjuvant melanoma

Clinical Practice

Intismeran Adjuvant Melanoma Trial Cuts Recurrence Risk by 42%

Merck and Moderna report a 42% reduction in recurrence or death for intismeran plus KEYTRUDA in resected stage IIB-IV melanoma, with full data at ESMO 2026. #SyenzaNews #melanoma #MarketAccess

Syenza TeamRead ›
neuroscience medical product development

Alzheimer's Disease

FDA Launches Neuroscience Medical Product Development Program

The FDA has launched the Neuroscience Advancement and Innovation Nexus, starting with an Alzheimer’s Prevention Accelerator. #SyenzaNews #Alzheimers #MarketAccess

Syenza TeamRead ›
clinical AI governance framework

Artificial Intelligence And Machine Learning

Clinical AI governance framework guides AI tool evaluation

A new npj Digital Medicine article in press from SCPMG proposes the C-TACT clinical AI governance framework, with weighted lifecycle scorecards and its limits stated.

Syenza TeamRead ›